In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Practice Guideline Track on Atrial Fibrillation

Guidelines into Practice

Cardiovascular Pharmacology and Pharmacotherapy
Invasive Electrophysiology and Ablation
Atrial Fibrillation


Contributor: Special thanks to Haran Burri from the European Heart Rhythm Association (EHRA).

Based on the ESC Clinical Practice Guidelines on Atrial Fibrillation (Management of) 2010 and Focused Update (2012).

Part 1 - Overview of the 2012 focused update on ESC guidelines on management of Atrial Fibrillation (AF)

Session Title  Slides Webcast
2012 ESC Guidelines overview :Atrial fibrillation focused update.    
Update on Consensus statement on management of Afib EHRA 2012
Atrial fibrillation ablation: in whom and how. Update of HRS/EHRA AF/ECAS ablation document 2012    
Update on ESC AF guidelines on medical therapy 2012.    
2012 update of the ESC guidelines of the management of  atrial fibrillation
Risk prediction for stroke in atrial fibrillation      
Selection of antithrombotic therapy for  atrial fibrillation: integration of stroke and bleeding risk      
Antiarrhythmic drug therapy for prevention of atrial fibrillation recurrences.      
Cardioversion of atrial fibrillation.      
Interventional techniques for the management of atrial fibrillation.      
Current guidelines: why they confuse us.     

Part 2 - Topics in focus

Topic Session Title Slides Webcast
ANTITHROMBOTIC THERAPY


Left atrial appendage closure is the therapy of choice for many patients with atrial fibrillation.: Pro.    
Left atrial appendage closure is the therapy of choice for many patients with atrial fibrillation.: Contra.    
Is there still a role for vitamin K antagonists?    
Are trials comparable?    
Bleeding risk. The dark side of anticoagulant drugs.      
Which anticoagulant for which patient?       
Navigating a changing landscape: what factors should we consider when choosing an anticoagulant for stroke prevention?     
Case scenario: meet the experts        
   The 74 year old man with peripheral artery disease - how to assess risks of stroke, bleeding and falls.      
  The young female patient undergoing AF ablation - should we anticoagulate?      
ANTIARRHYTHMIC  THERAPY Vernakalant is the first choice for cardioversion in patients with a normal heart.: Contra.     
Dronedarone is an important drug in the management of paroxysmal atrial fibrillation.: Pro.     
Dronedarone is an important drug in the management of paroxysmal atrial fibrillation.: Contra.     
AF IN THE ELDERLY  The magnitude of the problem.     
Use of anticoagulants      
Must we treat rhythm?     
CATHETER ABLATION OF AF Prevalence and predictors of complications     
Catheter ablation on uninterrupted warfarin: risks and benefits.     
Incidence of silent thromboembolic lesions.